Business Wire

Thales Named as a Market Leader in KuppingerCole Analysts Leadership Compass for Enterprise Authentication

9.3.2021 18:28:00 EET | Business Wire | Press release

Share

Thales today announced that it has been named as a Market Leader in the 2021 KuppingerCole Leadership Compass for Enterprise Authentication.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005761/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Copyright Thales

The report recognised Thales as a global leader within the enterprise authentication market through its SafeNet Trusted Access offer. Thales’ primary access management capability received accolades for its authentication support, authorisation and policy management, in addition to strong reporting capabilities, modern user interfaces (UIs) and dashboards. SafeNet Trusted Access supports public cloud and a hybrid deployment model delivered by Managed Service Providers. KuppingerCole evaluated Thales’ standing, following a detailed analysis of other industry players, market reach and analysis of product capabilities.

“Thales’ core enterprise authentication capabilities include good support for basic hardware tokens and popular mobile and cloud app authentication methods. Customers are typically drawn by the high-security options SafeNet provides. Organisations, in both the public and private sectors that need high strength MFA options may want to consider Thales’ SafeNet Suite,” said John Tolbert, Lead Analyst at KuppingerCole.

With more organisations storing data on the cloud than ever before, access management ensures businesses can mitigate the threat of data breaches and simplify cloud access. According to Thales’ 2020 Access Management Index – Europe and Middle East Edition 1, over half (57%) of IT decision makers in Europe and the Middle East identified unprotected infrastructure, such as IoT devices, as the biggest target for cyber-attacks, while nine in 10 (96%) believe that strong authentication and access management solutions can facilitate secure cloud adoption.

“Over the past year, we have witnessed a vast migration to cloud technology as these services become increasingly essential in the current climate with more people working remotely than ever before. However, this move of embracing the cloud for mission-critical applications and IT infrastructure brings increased risk for businesses,” said François Lasnier, Vice President for Access Management solutions at Thales. “As result, we are extremely pleased to have been identified by KuppingerCole as a leader in authentication and access management through SafeNet Trusted Access. This demonstrates Thales’ continued strength, reach and commitment to address customers’ security, compliance and end users’ needs in this new digital-first world.”

SafeNet Trusted Access is a cloud-based access management solution that combines the convenience of single sign-on (SSO) with granular access security controls and adaptive authentication. Through validating identities, enforcing access policies and applying Smart SSO, SafeNet Trusted Access helps companies to meet compliance needs, secure convenient access to cloud applications and prevent data breaches.

Download the full KuppingerCole Report Leadership Compass for Access Management.

Industry insight and views on the latest data security trends can be found on the Thales blog. Follow Thales on Twitter, LinkedIn, Facebook and YouTube .

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.

---

1 The 2020 Access Management Index, is a survey of 400 executives in 7 countries in Europe and the Middle East with responsibility for, or influence over, IT and data security. The survey, reporting and analysis was conducted by Vanson Bourne, commissioned by Thales.

PLEASE VISIT
Thales Group
Security
Download HD photos

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT
Thales, Media Relations

Security
Laura Bandiera
+33 (0)7 64 48 51 64
laura.bandiera@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye